Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

IN-TIME shows equal benefit of home telemonitoring in ICD and CRT-D patients

19.05.2014

ICD patients and CRT-D patients benefit to an almost equivalent extent from home telemonitoring

Home telemonitoring is equally effective in ICD and CRT-D patients, a subanalysis of the IN-TIME trial has shown. The findings were presented for the first time today at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

The prospective IN-TIME multicentre trial included 664 patients with chronic heart failure, class II or III New York Heart Association (NYHA) symptoms and left ventricular ejection fraction <35% who were receiving optimal medical therapy. Nearly two-thirds of patients (60%) received a cardiac resynchronisation defibrillator (CRT-D) while 40% received an implantable cardioverter defibrillator (ICD).

All of the implanted devices had a home telemonitoring capability. Patients were randomised in a 1:1 fashion to have the telemonitoring function switched on or off. For those patients who had the telemonitoring function switched on, data from their device was transmitted to a monitoring physician or clinic to enable early detection of arrhythmias or other complications. Patients with the telemonitoring switched off were followed up during visits to the clinic.

... more about:
»CRT-D »Cardiology »ICD »failure »mortality »receiving »risk »therapy

The findings of the overall study were presented at ESC Congress 2013. Briefly, the trial showed that telemonitoring reduced the proportion of patients with a worsened composite clinical score consisting of all cause mortality, overnight hospitalisation for worsened heart failure, change in NYHA class, and change in patient global self assessment from 27.2% to 18.9% (p=0.013) (primary outcome). Telemonitoring also reduced one-year mortality from 8.7% to 3.4% (p=0.004) (secondary outcome).

The current subanalysis of the IN-TIME trial, presented for the first time today, investigated whether home telemonitoring was equally effective in patients with a CRT-D and patients with an ICD.

Professor Gerhard Hindricks, principal investigator of the study, said: "We predefined this subanalysis because we wanted to know if our overall findings were the same in both device types. This would have an impact on the interpretation of the data and recommendations for treatment in these patient populations."

He continued: "The patient population receiving a CRT-D is quite different to the patient population receiving an ICD. Usually the patients with an indication for CRT implantation are at higher risk of worsening of heart failure during the natural course of the disease, and they profit more from defibrillator therapy with a cardiac resynchronisation function."

The researchers found that the relative risk of the primary outcome in the telemonitoring versus control group was similar in the ICD (0.61, p=0.06) and CRT-D (0.75, p=0.10) patients. The relative risk of the secondary outcome was also similar in both device groups (ICD: 0.38, p=0.15; CRT-D: 0.35, p=0.014).

Professor Hindricks said: "This subanalysis adds to the general finding of the IN-TIME trial. We now know that ICD patients and CRT-D patients benefit to an almost equivalent extent from home telemonitoring."

He concluded: "The take home message for clinicians is that if you have a patient with advanced heart failure and an ejection fraction less than 35% who is on optimal medical therapy, consider implantation of an ICD or CRT-D that is capable of home telemonitoring. Patients on both types of devices will benefit equally from home telemonitoring, with improved clinical outcomes including reduced mortality."

Jacqueline Partarrieu | Eurek Alert!
Further information:
http://www.escardio.org

Further reports about: CRT-D Cardiology ICD failure mortality receiving risk therapy

More articles from Health and Medicine:

nachricht Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University

nachricht The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

Im Focus: Molecules change shape when wet

Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water

In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

IHP presents the fastest silicon-based transistor in the world

05.12.2016 | Power and Electrical Engineering

InLight study: insights into chemical processes using light

05.12.2016 | Materials Sciences

High-precision magnetic field sensing

05.12.2016 | Power and Electrical Engineering

VideoLinks
B2B-VideoLinks
More VideoLinks >>>